Armata Pharmaceuticals, Inc. (ARMP) |
|
2.97 0.3 (11.24%)
|
09-27 11:02 |
|
Open: |
2.74 |
Pre. Close: |
2.67 |
|
High:
|
3.169 |
Low:
|
2.74 |
|
Volume:
|
18,934 |
Market Cap:
|
107(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:45:14 AM |
|
Short-term rate:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 3.79  One year: 4.3 |
| Support: |
Support1: 2.52 Support2: 2.1 |
| Resistance: |
Resistance1: 3.24 Resistance2: 3.69 |
| Pivot: |
2.83 |
| Moving Average: |
MA(5): 2.72 MA(20): 2.95
MA(100): 2.17 MA(250): 2.29 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 25.1 %D(3): 16.7 |
| RSI: |
RSI(14): 51.8 |
| 52-week: |
High: 5.26 Low: 0.82 |
| Average Vol(K): |
3-Month: 186 (K) 10-Days: 27 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARMP ] has closed below upper band by 25.9%. Bollinger Bands are 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.73 - 2.75 |
2.75 - 2.76 |
|
Low:
|
2.61 - 2.63 |
2.63 - 2.65 |
|
Close:
|
2.64 - 2.67 |
2.67 - 2.7 |
|
Company Description |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
Headline News |
Tue, 26 Sep 2023
Armata Pharmaceuticals Announces First Patient Dosed in the ... - PR Newswire
Thu, 21 Sep 2023
Armata Pharmaceuticals to Participate in the Cantor Global ... - PR Newswire
Tue, 22 Aug 2023
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why - Zacks Investment Research
Mon, 14 Aug 2023
Armata Pharmaceuticals Announces Second Quarter 2023 Results ... - BioSpace
Mon, 24 Jul 2023
Armata, Janux top healthcare gainers; Kodiak, BioCardia lead losers ... - Seeking Alpha
Tue, 11 Jul 2023
Armata Pharmaceuticals Announces New Financing and ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
